The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

The U.S. Food and Drug Administration (FDA) has released several important updates addressing new medication approvals and significant changes in pharmaceutical labeling, marking advancements in ...

Some 85% of LTC pharmacies might limit essential services and 60% will close locations without changes to Medicare drug ...

The US Food and Drug Administration (FDA) has approved the first generics of Xarelto (rivaroxaban), a cardio vascular drug developed by Germany’s Bayer and marketed in the USA by Johnson & Johnson.

Janssen Pharms' Xarelto is prescribed to reduce the risk ... for months after the CMS selected 10 high-priced, single-source drugs that didn't have generic or competitor versions to renegotiate ...

Lupin is introducing rivaroxaban tablets, 2.5 mg, which is the generic of Janssen’s Xarelto. The medication is used to reduce the risk of major cardiovascular events in patients with coronary ...

J&J – which jointly developed Xarelto with Bayer – has US commercial rights to the drug and sells it as 2.5mg, as well as 10mg, 15mg, and 25mg tablets, along with a 1mg/ml oral suspension ...

Bayer and Janssen’s novel oral anticoagulant (NOAC) Xarelto has a new string to its bow after the FDA approved it to prevent blood clots in acutely ill medical patients. The drug, marketed by ...

Those drugs were Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara and Fiasp/NovoLog. CMS is following a certain set of parameters to determine which drugs are ...

While Xarelto sales fell 15% from 4.1 billion euros ... The gain comes as Bayer’s partner Regeneron—which commercializes the drug in the U.S.—has seen a slight decline in sales over the ...